Profile data is unavailable for this security.
About the company
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.
- Revenue in USD (TTM)0.00
- Net income in USD-9.29m
- Incorporated2011
- Employees6.00
- LocationArtelo Biosciences Inc505 LOMAS SANTA FE, SUITE 160SOLANA BEACH 92075United StatesUSA
- Phone+1 (858) 925-7049
- Websitehttps://artelobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zyversa Therapeutics Inc | 0.00 | -106.25m | 3.98m | 7.00 | -- | 0.1917 | -- | -- | -1,922.89 | -1,922.89 | 0.00 | 27.33 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Aditxt Inc | 645.19k | -32.70m | 4.01m | 47.00 | -- | 0.198 | -- | 6.22 | -153.12 | -153.12 | 2.14 | 12.17 | 0.0233 | 0.8927 | 1.38 | 13,727.45 | -117.12 | -192.78 | -251.19 | -321.59 | -17.30 | -- | -5,020.30 | -7,208.65 | 0.2382 | -4.09 | 0.5020 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Evoke Pharma Inc | 5.18m | -7.79m | 4.07m | 4.00 | -- | -- | -- | 0.7855 | -2.33 | -2.33 | 1.55 | -0.7716 | 0.5476 | 0.5235 | 7.98 | 1,295,158.00 | -82.37 | -100.48 | -109.52 | -151.10 | 96.10 | -- | -150.41 | -480.52 | 2.09 | -20.56 | 2.07 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 4.07m | 208.00 | -- | 0.5881 | 10.19 | 0.116 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| Axim Biotechnologies Inc | 39.77k | -8.06m | 4.18m | 6.00 | -- | -- | -- | 105.01 | -0.0366 | -0.0366 | 0.0001 | -0.0311 | 0.0095 | -- | -- | 6,628.33 | -193.43 | -154.34 | -- | -390.73 | -- | -- | -20,265.75 | -36,362.71 | -- | -0.62 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -9.29m | 4.20m | 6.00 | -- | 0.3528 | -- | -- | -3.12 | -3.12 | 0.00 | 3.69 | 0.00 | -- | -- | 0.00 | -55.51 | -- | -59.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| SYBLEU Inc | 11.70k | -307.88k | 4.30m | -- | -- | -- | -- | 367.87 | -0.0293 | -0.0293 | 0.0011 | -0.0367 | 0.0641 | -- | -- | -- | -168.63 | -- | -- | -- | -- | -- | -2,631.45 | -- | -- | -8.48 | 4.96 | -- | 0.00 | -- | 26.51 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -16.08m | 4.32m | 10.00 | -- | 3.87 | -- | -- | -35.76 | -35.76 | 0.00 | 0.7136 | 0.00 | -- | -- | 0.00 | -167.56 | -70.80 | -206.12 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| China Pharma Holdings Inc | 7.01m | -3.08m | 4.34m | 231.00 | -- | 0.4171 | -- | 0.6184 | -1.06 | -1.06 | 2.07 | 0.7016 | 0.4094 | 2.18 | 15.14 | 30,351.95 | -17.98 | -29.66 | -41.91 | -55.25 | -4.01 | 6.47 | -43.91 | -73.09 | 0.332 | -8.42 | 0.3121 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.01m | 4.35m | 3.00 | -- | -- | -- | -- | -0.1397 | -0.1397 | 0.00 | -0.8107 | 0.00 | -- | -- | 0.00 | -457.45 | -- | -- | -- | -- | -- | -- | -- | -- | -35.84 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| Neximmune Inc | 0.00 | -32.34m | 4.36m | 6.00 | -- | 0.9661 | -- | -- | -30.86 | -30.86 | 0.00 | 3.29 | 0.00 | -- | -- | 0.00 | -125.24 | -115.07 | -178.52 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| GT Biopharma Inc | 0.00 | -7.60m | 4.38m | 2.00 | -- | 0.5855 | -- | -- | -5.57 | -5.57 | 0.00 | 5.41 | 0.00 | -- | -- | 0.00 | -49.26 | -205.36 | -78.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Exicure Inc | 23.79m | 3.07m | 4.41m | 7.00 | 0.399 | 0.4545 | 1.07 | 0.1854 | 1.28 | 1.28 | 3.86 | 1.12 | 0.8729 | -- | -- | 1,830,000.00 | 11.25 | -41.75 | 18.34 | -55.57 | -- | -- | 12.88 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
| Marijuana Company Of America Inc | 1.50m | -13.01m | 4.42m | 7.00 | -- | -- | -- | 2.95 | -0.0071 | -0.0071 | 0.0003 | -0.0036 | 0.3137 | 5.61 | 7.64 | 214,085.70 | -272.25 | -837.07 | -- | -- | 28.37 | 39.75 | -867.96 | -3,809.92 | 0.031 | -0.6498 | -- | -- | 267.09 | 159.65 | 16.09 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -9.32m | 4.42m | 2.00 | -- | 0.4821 | -- | -- | -13.09 | -13.09 | 0.00 | 0.7778 | 0.00 | -- | -- | 0.00 | -105.69 | -- | -127.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Marizyme Inc | 590.91k | -79.15m | 4.43m | 13.00 | -- | -- | -- | 7.50 | -1.83 | -1.83 | 0.0139 | -0.4704 | 0.0117 | 0.9575 | 12.13 | 45,454.62 | -157.28 | -29.47 | -314.26 | -30.42 | 71.63 | 67.78 | -13,393.85 | -8,518.47 | 0.025 | -0.5887 | -- | -- | 11.04 | 18.20 | -247.03 | -- | -- | -- |
Data as of May 01 2024. Currency figures normalised to Artelo Biosciences Inc's reporting currency: US Dollar USD
0.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Dec 2023 | 19.81k | 0.61% |
| Tower Research Capital LLCas of 31 Dec 2023 | 4.80k | 0.15% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Dec 2023 | 22.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 20.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2023 | 7.00 | 0.00% |
| NewEdge Advisors LLCas of 31 Dec 2023 | 1.00 | 0.00% |
| Strategic Advisers LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| UBS Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| HRT Financial LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| PNC Bank, NA (Investment Management)as of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
